Not Yet RecruitingNot Applicable

Electrotherapeutic Interventions for Glenohumeral Subluxation After Stroke

Turkey (Türkiye)36 participantsStarted 2026-02-27

Plain-language summary

The aim of this single-blind randomized controlled trial is to compare the effects of two therapies-neuromuscular electrical stimulation (NMES) and electromyographic (EMG) biofeedback-in stroke patients with shoulder (glenohumeral) subluxation. The study will evaluate changes in shoulder structure and function by measuring the acromion-greater tuberosity distance, supraspinatus and posterior deltoid muscle thickness, shoulder range of motion, and Brunnstrom stage of the upper extremity and hand. Clinical outcomes such as shoulder pain, stroke-specific quality of life, and the Shoulder Pain and Disability Index (SPADI) will also be assessed. This trial is designed to provide evidence on which therapy may be more effective for improving shoulder stability, reducing pain, and enhancing quality of life in stroke survivors with shoulder subluxation.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18 years of age, * Disease duration \>3 months, * Glenohumeral subluxation (GHS) confirmed by ultrasonography (USG), * Upper extremity and hand Brunnstrom motor stages between 2 and 5 Exclusion Criteria: * Mini-Mental State Examination (MMSE) score \<24, * Visual/hearing impairments, or neglect, * Steroid injection for shoulder pain within the last 3 months, * Unstable systemic disease, * Spasticity with Modified Ashworth Scale (MAS) score 3-4, * Presence of metal implants or pacemaker

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Acromion-Greater Tuberosity Distance (AGT Distance) - Musculoskeletal Ultrasound Measurement

Timeframe: Baseline and Week 3

Supraspinatus Muscle Thickness Measured by Musculoskeletal Ultrasound

Timeframe: Baseline (Week 0) and Week 3

Posterior Deltoid Muscle Thickness Measured by Musculoskeletal Ultrasound

Timeframe: Baseline (Week 0) and Week 3

Motor Function

Timeframe: Baseline and Week 3

Trial details

NCT IDNCT07423455

SponsorŞahide Eda ARTUÇ

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-27

Contact for this trial

ŞAHİDE E ARTUÇ, MD

+905534488730 edartuc@gmail.com

View on ClinicalTrials.gov More Glenohumeral Subluxation trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Acromion-Greater Tuberosity Distance (AGT Distance) - Musculoskeletal Ultrasound Measurement

Timeframe: Baseline and Week 3

Supraspinatus Muscle Thickness Measured by Musculoskeletal Ultrasound

Timeframe: Baseline (Week 0) and Week 3

Posterior Deltoid Muscle Thickness Measured by Musculoskeletal Ultrasound

Timeframe: Baseline (Week 0) and Week 3

Motor Function

Timeframe: Baseline and Week 3